Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the change in body weight from baseline and to assess the safety and tolerability of JNJ-64565111 in non-diabetic severely obese participants.

Key Inclusion / Exclusion Criteria:
  • Men and women age 18-70 
  • BMI ≥ 35 to ≤ 5 0 kg/m2 at the screening visit 
  • Stable weight (that is, change of < 5% within 12 weeks before screening based on medical history) 
  • No personal history of the following: Type 1 diabetes mellitus, T2DM, MI, unstable angina, revascularization procedure cardiac pacemaker or other electric implantable device, significant liver disease, pancreatitis, bariatric surgical procedure or a known clinically significant gastric emptying abnormality 
  • Detailed eligibility reviewed when you contact the study team. 

This clinical trial is for men and women with glioblastoma that has recurred or progressed. There is currently a need for more effective treatment methods for this disease. 

Key Inclusion / Exclusion Criteria:
  • Open to men and women above the age of 18 
  • Diagnosed with glioblastoma (GBM) at first recurrence or progression following primary therapy consisting of surgery (biopsy or resection) and chemoradiation 
  • Detailed eligibility will be reviewed when you contact the study team 

Complicated intra-abdominal infections, also referred to as cIAIs, are serious bacterial infections of the abdomen such as: 

• Burst appendix: when an infected appendix, a pouch connected to the large intestine, bursts 

Key Inclusion / Exclusion Criteria:

You might be able to take part in the Caspian-Andi study if you:
• Are between 3 months and up to (but not including) 18 years old
• Have a complicated infection of the abdomen (cIAI)
• Need surgery and antibiotic therapy (via a tube in the vein or ‘IV’) to help treat your infection

Other criteria will be discussed with the study team.

This clinical trial is for men and women with meningioma. Currently available treatments are not effective in treating patients with this disease. Therefore, there is a need to find treatments that work for patients with meningoioma.

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older
  • Diagnosis of meningioma
  • Open to untreated and previously treated patients
  • Detailed eligibility reviewed when you contact the study team.

The purpose of this study is to examine brain cancer patients’ surgically removed tumors for certain molecular changes that may make them eligible to participate in the related treatment study. 

Key Inclusion / Exclusion Criteria:

   • Open to men and women age 18 and older 
   • Patients have not had a local MGMT testing 
   • Newly diagnosed Grade IV intracranial gliobastoma or gliosarcoma 
   • Patients must have completed standard radiotherapy and TMZ therapy 
   • No other therapy has been done (Neoadjuvant or adjuvant) which includes chemotherapy, biologics, immunotherapy, and radiation therapy. 
   • Detailed eligibility reviewed when you contact the study team.

This clinical trial is for men and women age ≥ 18 years old who have been diagnosed with advanced rectum cancer.

Key Inclusion / Exclusion Criteria:

   • Open to men and women, Age ≥18 years at the time of informed consent who have been diagnosed with invasive primary rectal cancer
   • No prior pelvic radiotherapy, chemotherapy, immunotherapy or other anti-cancer treatment for rectal cancer
   • Ability to read and provide signed informed consent. Patients may not be consented by a durable power of attorney.
   • Ability and willingness to comply with scheduled study visits, treatment plans, laboratory tests and other study related procedures 

Additional eligibility criteria reviewed when you contact the study team. 

Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.

This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery.

This clinical trial is for men with high risk, localized prostate cancer. The most common treatment options for men with clinically localized prostate cancer include radical prostatectomy (surgical removal of the prostate) and radiation therapy (uses radiation to kill cancer cells).

Key Inclusion / Exclusion Criteria:
  • Men age 18 and older. 
  • Diagnosis of prostate cancer 
  • No prior treatment for prostate cancer. 
  • Detailed eligibility reviewed when you contact the study team. 

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.